Opioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment

References

• Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book. 2015;35:e593–599.
   Google Scholar
• Oosten AW, Oldenmenger WH, Mathijssen RH, et al. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16:935–946.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Traitement de la douleur cancéreuse. Geneva : World Health Organization; 1987.
   Google Scholar
• Li X, Dong Y, Li H, et al. Advances in the use of opioids in treating neuropathic cancer pain. Ann Palliat Med. 2012;1:53–57.
   PubMedGoogle Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–465.
   PubMed Web of Science ®Google Scholar
• Trescot AM. Review of the role of opioids in cancer pain. J Natl Compr Canc Netw. 2010;8:1087–1094.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer. 1989;63:2298–2307.
   PubMed Web of Science ®Google Scholar
• Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16:1423–1433.
   PubMedGoogle Scholar
• Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol. 2014;2:31–37.
   PubMedGoogle Scholar
• Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15:344.
   PubMedGoogle Scholar
• Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847–1865.
   PubMed Web of Science ®Google Scholar
• Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Devel Ther. 2015;9:2215–2231.
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.
   PubMed Web of Science ®Google Scholar
• Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud. 1989;26:69–79.
   PubMed Web of Science ®Google Scholar
• Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer. 2004;12:613–618.
   PubMed Web of Science ®Google Scholar
• Plante GE, VanItallie TB. Opioids for cancer pain: the challenge of optimizing treatment. Metabolism. 2010;59(Suppl 1):S47–52.
   Google Scholar
• Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology. 1997;113:409–414.
   PubMed Web of Science ®Google Scholar
• Ratuapli SK, Crowell MD, DiBaise JK, et al. Opioid-Induced Esophageal Dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110:979–984.
   PubMed Web of Science ®Google Scholar
• Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther. 2010;31:601–606.
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF, O’Connor M, et al. Effects of low-dose morphine on gastric emptying in healthy volunteers. J Clin Pharmacol. 1998;38:1017–1020.
   PubMed Web of Science ®Google Scholar
• Turnberg LA. Antisecretory activity of opiates in vitro and in vivo in man. Scand J Gastroenterol Suppl. 1983;84:79–83.
   PubMedGoogle Scholar
• Kromer W. Endogenous opioids, the enteric nervous system and gut motility. Dig Dis. 1990;8:361–373.
   PubMed Web of Science ®Google Scholar
• Sobczak M, Salaga M, Storr MA, et al. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014;49:24–45.
   PubMed Web of Science ®Google Scholar
• Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 2):17–28.
   PubMed Web of Science ®Google Scholar
• Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16:181–194.
   PubMed Web of Science ®Google Scholar
• Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988;94:1351–1356.
   PubMed Web of Science ®Google Scholar
• Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192–195.
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–671.
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S–18S.
   PubMed Web of Science ®Google Scholar
• Bauer AJ, Sarr MG, Szurszewski JH. Opioids inhibit neuromuscular transmission in circular muscle of human and baboon jejunum. Gastroenterology. 1991;101:970–976.
   PubMed Web of Science ®Google Scholar
• De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103–115.
   PubMed Web of Science ®Google Scholar
• Calignano A, Moncada S, Di Rosa M. Endogenous nitric oxide modulates morphine-induced constipation. Biochem Biophys Res Commun. 1991;181:889–893.
   PubMed Web of Science ®Google Scholar
• Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014: 141737.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lee JS, Viramontes B, et al. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc. 2000;48:1142–1150.
   PubMed Web of Science ®Google Scholar
• Varma JS, Bradnock J, Smith RG, et al. Constipation in the elderly. A physiologic study. Dis Colon Rectum. 1988;31: 111–115.
   PubMed Web of Science ®Google Scholar
• Koch TR, Carney JA, Go VL, et al. Inhibitory neuropeptides and intrinsic inhibitory innervation of descending human colon. Dig Dis Sci. 1991;36:712–718.
   PubMed Web of Science ®Google Scholar
• Shook JE, Pelton JT, Hruby VJ, et al. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243:492–500.
   PubMed Web of Science ®Google Scholar
• Costilla VC, Foxx-Orenstein AE. Constipation: understanding mechanisms and management. Clin Geriatr Med. 2014;30:107–115.
   PubMed Web of Science ®Google Scholar
• Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2015;49:9–16.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924.
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
   PubMed Web of Science ®Google Scholar
• Rentz AM, Van Hanswijck De Jonge P, Leyendecker P, et al. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011;27:35–44.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324–2337.
   PubMed Web of Science ®Google Scholar
• Marquis P, De La Loge C, Dubois D, et al. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol. 2005;40:540–551.
   PubMed Web of Science ®Google Scholar
• Dhingra L, Shuk E, Grossman B, et al. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2013;27:447–456.
   PubMed Web of Science ®Google Scholar
• Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92:95–98.
   PubMed Web of Science ®Google Scholar
• Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005;100:232–242.
   PubMed Web of Science ®Google Scholar
• Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database Syst Rev. 2014;3:CD008486.
   Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.
   PubMed Web of Science ®Google Scholar
• Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A Systematic Review. Palliat Med. 2011;25:494–503.
   PubMed Web of Science ®Google Scholar
• Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;3:CD004847.
   Google Scholar
• Liu LW. Chronic constipation: current treatment options. Can J Gastroenterol. 2011;25(Suppl B):22b–28b.
   PubMedGoogle Scholar
• Skollerud LM, Fredheim OM, Svendsen K, et al. Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database. Support Care Cancer. 2013;21:67–73.
   PubMed Web of Science ®Google Scholar
• Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22:796–807.
   PubMed Web of Science ®Google Scholar
• Candy B, Jones L, Larkin PJ, et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev 2015;5:Cd003448.
   PubMed Web of Science ®Google Scholar
• Lee-Robichaud H, Thomas K, Morgan J et al. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;7:CD007570.
   PubMed Web of Science ®Google Scholar
• Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291:930–932.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
   PubMed Web of Science ®Google Scholar
• Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912–2921.
   PubMed Web of Science ®Google Scholar
• Sood R, Ford AC. Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Ther Adv Chronic Dis. 2013;4:268–276.
   PubMedGoogle Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–1712.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–947.
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35:587–599.
   PubMed Web of Science ®Google Scholar
• Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014;15: 1825–1834.
   PubMed Web of Science ®Google Scholar
• Jamal MM, Adams AB, Jansen JP, et al. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol. 2015;110:725–732.
   PubMed Web of Science ®Google Scholar
• Spierings EL, Rauck R, Brewer R, et al. Long-term safety and efficacy of lubiprostone in opioid-induced constipation in patients with chronic noncancer pain. Pain Pract. 2015. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Anantharamu T, Sharma S, Gupta AK, et al. Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother 2015;6:188–192.
   PubMed Web of Science ®Google Scholar
• Chappell D, Rehm M, Conzen P. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;359:1071. author reply 1071
   PubMed Web of Science ®Google Scholar
• Bader S, Jaroslawski K, Blum HE, et al. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201–211.
   PubMedGoogle Scholar
• Mackey AC, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. 2010;40:e1–3.
   PubMedGoogle Scholar
• Bream-Rouwenhorst HR, Cantrell MA. Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009;66:1267–1277.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12:185–193.
   PubMed Web of Science ®Google Scholar
• Corsetti M, Tack J. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. Drugs Today (Barc). 2015;51:479–489.
   PubMed Web of Science ®Google Scholar
• Corsetti M, Tack J. Naloxegol, a new drug for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2015;16:399–406.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015;75:419–425.
   PubMed Web of Science ®Google Scholar
• Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–2396.
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50–60.
   PubMed Web of Science ®Google Scholar
• Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011;65:472–478.
   PubMed Web of Science ®Google Scholar
• Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010;26:1377–1387.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Russo G, Esposito G, et al. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study. Am J Hosp Palliat Care. 2014;31:867–876.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011;19:1471–1472.
   PubMed Web of Science ®Google Scholar
• Leppert W. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets. 2014;15:124–135.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39:239–253.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009–1015.e3.
   Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011;106:1803–1812.
   PubMed Web of Science ®Google Scholar